A new beginning: can omidubicel emerge as the next, viable alternative donor source?
Umbilical cord blood (UCB) transplantation (CBT) has been an important alternative donor option for patients lacking matched related donor (MRD) or unrelated donor (URD) grafts. Only 30% of patients with high-risk hematologic malignancies have a human leukocyte antigen (HLA)-identical sibling; subje...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
SAGE Publishing
2023-08-01
|
| Edice: | Therapeutic Advances in Hematology |
| On-line přístup: | https://doi.org/10.1177/20406207231192146 |